Similarly, the myostatin antibody trials (conducted by Roche—NCT03039686 and Pfizer—NCT02907619) similarly fell short of the primary endpoint, casting doubt on the efficacy of this approach for DMD patients [45]. This evidence concerns the gene MSTN and Duchenne muscular dystrophy.